Catalyst Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Catalyst Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Catalyst Pharmaceuticals Inc Strategy Report
- Understand Catalyst Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Catalyst Pharmaceuticals Inc (Catalyst) is a biopharmaceutical company that develops and commercializes prescription drugs targeting rare neurological and neuromuscular diseases. The company focuses on specific conditions such as lambert-eaton myasthenic syndrome (LEMS) and focal onset seizures. The company also has various existing agreements to commercialize its products. Its product portfolio includes Firdapse, a proprietary form of amifampridine phosphate for the treatment of LEMS in children and adults. The company operates in the US and through its subsidiary in Ireland. Catalyst is headquartered in Coral Gables, Florida, the US.
Headquarters
United States of America
Address
355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134
Website
catalystpharma.com
Telephone
1 305 5292522
No of Employees
167
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CPRX (NASD)
Revenue (2022)
$398.2M
85.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-14%
(2022 vs 2021)
Market Cap*
$1.7B
Net Profit Margin (2022)
XYZ
-53.8%
(2022 vs 2021)
* As of and is in US$
Catalyst Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Firdapse: Lambert-Eaton Myasthenic Syndrome (LAMS) | Firdapse |
| Fycompa: Focal onset seizures | Agamree |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In January, the company announced the acquisition of U.S. rights to FYCOMPA(R) (Perampanel) CIII. |
| 2021 | Contracts/Agreements | In June, the company entered into an license and supply agreement with DyDo Pharma, Inc. for the enhancement and commercialization of Firdapse (amifampridine) Tablets 10 mg in Japan. |
| 2020 | Contracts/Agreements | In April, the company entered into corporate partnership with First Responders Children’s foundation to support the COVID-19 emergency response fund. |
Competitor Comparison
| Key Parameters | Catalyst Pharmaceuticals Inc | GSK plc | Marinus Pharmaceuticals Inc | Jacobus Pharmaceutical Co Inc | Marathon Pharmaceuticals LLC (Inactive) |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Coral Gables | Brentford | Radnor | Plainsboro | Northbrook |
| State/Province | Florida | England | Pennsylvania | New Jersey | Illinois |
| No. of Employees | 167 | 70,212 | 165 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick J. McEnany | Co-Founder; Chairman | Executive Board | 2006 | - |
| Richard J. Daly | Chief Executive Officer; Director | Executive Board | 2024 | - |
| Michael W. Kalb | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | - |
| Preethi Sundaram | Chief Strategy Officer | Senior Management | - | - |
| Brian Elsbernd | Chief Compliance Officer; Chief Legal Officer | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer